Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Myeloproliferative neoplasms in Mexico: An analysis of clinical features, driver mutations, and disease progression patterns in a case series.

View Full Paper
Ask AI
Bookmark
Share

Authors

KUKatya Unzueta-VillalobosDRDiana Romero-Terrazas

Discussion

Loading...

Member takes

Overview

Retrospective case series shows high thrombosis prevalence and mortality in myeloproliferative neoplasms, indicating critical management needs.

Key Points

  • This study aims to analyze the clinical features, driver mutations, and disease progression of myeloproliferative neoplasms in Mexican patients.
  • Retrospective case series of 63 adult patients diagnosed with MPNs according to WHO criteria.
  • Data collected included demographic information, reported mutations, treatments, disease progression, and outcomes.
  • Statistical analyses employed include Chi-square tests, Fisher tests, and ANOVA/Kruskal-Wallis tests.
  • Mean age at diagnosis was 59.9 years; ET showed a female predominance while PV and MF showed male predominance.
  • Thrombosis prevalence was significantly high: 50% in MF, 38.5% in PV, and 25% in ET.
  • Significant disease progression was observed in 30% of ET patients and 15.4% of PV patients, with atypical progression patterns noted.

Cite This Study

Unzueta-Villalobos et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4fbhttps://doi.org/10.1182/blood-2025-7328
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Single Center’s Experience in the Diagnosis and Treatment of Myeloproliferative Neoplasms2025
  2. 2Clinicopathological characteristics and outcome of patients with Philadelphia negative myeloproliferative neoplasms: first report from Upper Egypt2025
  3. 3Thrombotic Events and Overall Survival in BCR-ABL1 Negative Myeloproliferative Neoplasms: A Single-Center Analysis2026
  4. 4Epidemiology and outcomes of patients with myeloproliferative neoplasms in the United States: A SEER database analysis, years 2000-20212025
  5. 5Clinical and hematological profile of patients with philadelphia-negative myeloproliferative neoplasms: First report from the Ecuadorian registry2026